Sarepta Therapeutics, Inc. (NASDAQ:SRPT) Shares Bought by Janus Henderson Group PLC

Janus Henderson Group PLC grew its holdings in Sarepta Therapeutics, Inc. (NASDAQ:SRPT) by 14.2% during the third quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm owned 4,358,511 shares of the biotechnology company’s stock after acquiring an additional 543,143 shares during the period. Janus Henderson Group PLC’s holdings in Sarepta Therapeutics were worth $544,408,000 as of its most recent SEC filing.

Other hedge funds also recently added to or reduced their stakes in the company. Erste Asset Management GmbH bought a new position in Sarepta Therapeutics in the third quarter valued at about $79,425,000. Principal Financial Group Inc. lifted its position in Sarepta Therapeutics by 693.7% during the 2nd quarter. Principal Financial Group Inc. now owns 363,011 shares of the biotechnology company’s stock worth $57,356,000 after acquiring an additional 317,277 shares during the period. Rhumbline Advisers lifted its holdings in shares of Sarepta Therapeutics by 146.3% in the 2nd quarter. Rhumbline Advisers now owns 270,941 shares of the biotechnology company’s stock valued at $42,809,000 after buying an additional 160,942 shares during the period. Blair William & Co. IL increased its stake in Sarepta Therapeutics by 303.7% during the 2nd quarter. Blair William & Co. IL now owns 174,282 shares of the biotechnology company’s stock worth $27,537,000 after buying an additional 131,112 shares in the last quarter. Finally, Summit Partners Public Asset Management LLC lifted its holdings in Sarepta Therapeutics by 547.9% in the third quarter. Summit Partners Public Asset Management LLC now owns 138,118 shares of the biotechnology company’s stock valued at $17,250,000 after acquiring an additional 116,800 shares during the last quarter. 86.68% of the stock is owned by institutional investors and hedge funds.

Sarepta Therapeutics Stock Performance

Shares of Sarepta Therapeutics stock opened at $127.95 on Tuesday. The business has a 50-day simple moving average of $122.50 and a 200-day simple moving average of $131.48. The company has a debt-to-equity ratio of 0.93, a quick ratio of 3.03 and a current ratio of 3.84. The company has a market cap of $12.22 billion, a PE ratio of 102.36 and a beta of 0.77. Sarepta Therapeutics, Inc. has a one year low of $83.97 and a one year high of $173.25.

Analysts Set New Price Targets

Several equities analysts recently issued reports on SRPT shares. Jefferies Financial Group assumed coverage on Sarepta Therapeutics in a research report on Monday, October 21st. They issued a “buy” rating and a $165.00 price target on the stock. StockNews.com lowered shares of Sarepta Therapeutics from a “buy” rating to a “hold” rating in a research note on Wednesday, November 20th. Robert W. Baird decreased their target price on shares of Sarepta Therapeutics from $200.00 to $193.00 and set an “outperform” rating for the company in a research note on Thursday, November 7th. Evercore ISI decreased their target price on shares of Sarepta Therapeutics from $179.00 to $170.00 and set an “outperform” rating on the stock in a research report on Thursday, November 7th. Finally, Citigroup lowered their target price on shares of Sarepta Therapeutics from $176.00 to $160.00 and set a “neutral” rating for the company in a research note on Thursday, August 8th. One equities research analyst has rated the stock with a sell rating, two have given a hold rating, twenty have assigned a buy rating and one has assigned a strong buy rating to the company’s stock. Based on data from MarketBeat, Sarepta Therapeutics presently has a consensus rating of “Moderate Buy” and a consensus price target of $175.77.

Sarepta Therapeutics Profile

Sarepta Therapeutics, Inc, a commercial-stage biopharmaceutical company, focuses on the discovery and development of RNA-targeted therapeutics, gene therapies, and other genetic therapeutic modalities for the treatment of rare diseases. It offers EXONDYS 51 injection to treat duchenne muscular dystrophy (duchenne) in patients with confirmed mutation of the dystrophin gene that is amenable to exon 51 skipping; VYONDYS 53 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene that is amenable to exon 53 skipping; AMONDYS 45 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene; and ELEVIDYS, an adeno-associated virus based gene therapy for the treatment of ambulatory pediatric patients aged 4 through 5 years with duchenne with a confirmed mutation in the duchenne gene.